financetom
Business
financetom
/
Business
/
J.B. Hunt posts 12% rise in quarterly profit on cost savings
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
J.B. Hunt posts 12% rise in quarterly profit on cost savings
Oct 15, 2025 2:38 PM

Oct 15 (Reuters) - U.S. trucking firm J.B. Hunt

Transport Services on Wednesday reported a 12% rise in

third-quarter profit, driven by ongoing cost-cutting measures

initiated in response to a freight downturn in the industry.

Shares of the company were up 11% in after-market trading.

The trucking industry has been in decline since 2022, driven

by excess capacity, falling freight rates, and modest growth in

shipment volumes.

Experts anticipate the downturn will persist, with tariffs

imposed by U.S. President Donald Trump adding pressure and

delaying recovery.

The Arkansas-based company reported net earnings of $170.9

mln, or $1.76 per share, for the quarter ended September 30, up

from $152.1 mln, or $1.49 per share, a year ago.

It reported revenue of $3.05 billion, slightly lower than

$3.07 billion in the year-ago quarter, but above analysts'

estimate of $3.03 billion, according to data compiled by LSEG.

Revenue performance was driven by a 1% and 4% decline in

gross revenue per load in the intermodal and truckload segments,

respectively, the company said.

J.B. Hunt also noted an 8% decrease in load volume during

the reported quarter in its Integrated Capacity Solutions

segment and 1% in the Dedicated Contract Services segment, as

well as 8% fewer stops in Final Mile Services business.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Amazon Web Services Outage Disrupts Social Media, Airlines, Telecom Firms
Amazon Web Services Outage Disrupts Social Media, Airlines, Telecom Firms
Oct 20, 2025
08:36 AM EDT, 10/20/2025 (MT Newswires) -- Amazon.com's ( AMZN ) cloud platform, Amazon Web Services, reported a major outage early Monday, disrupting the operations of companies, websites and apps including airlines, social media and telecommunications. AWS said it's seen significant and increased error rates for multiple services in the eastern US due to an operational issue, according to an...
Dynex Capital Q3 Adjusted Earnings, Net Interest Income Rise vs Q2
Dynex Capital Q3 Adjusted Earnings, Net Interest Income Rise vs Q2
Oct 20, 2025
08:40 AM EDT, 10/20/2025 (MT Newswires) -- Dynex Capital ( DX ) reported Q3 adjusted earnings Monday of $0.25 per share, up from $0.22 in the prior quarter. Net interest income for the quarter ended Sept. 30 was $30.6 million, up from $23.1 million for the quarter ended June 30. Analysts' estimates were not available for comparison. ...
BRIEF-Brag House Holdings Merger Partner, House of Doge - The Official Corporate Arm of the Dogecoin Foundation - Makes History by Becoming the First Cryptocurrency Company To Buy A Professional Footb
BRIEF-Brag House Holdings Merger Partner, House of Doge - The Official Corporate Arm of the Dogecoin Foundation - Makes History by Becoming the First Cryptocurrency Company To Buy A Professional Footb
Oct 20, 2025
Oct 20 (Reuters) - Arm Holdings PLC: * BRAG HOUSE HOLDINGS MERGER PARTNER, HOUSE OF DOGE - THE OFFICIAL CORPORATE ARM OF THE DOGECOIN FOUNDATION - MAKES HISTORY BY BECOMING THE FIRST CRYPTOCURRENCY COMPANY TO BUY A PROFESSIONAL FOOTBALL CLUB Source text: Further company coverage: ...
AbbVie Says Upadacitinib Shows Superior Efficacy Over Humira in Late-Stage Rheumatoid Arthritis Trial
AbbVie Says Upadacitinib Shows Superior Efficacy Over Humira in Late-Stage Rheumatoid Arthritis Trial
Oct 20, 2025
08:40 AM EDT, 10/20/2025 (MT Newswires) -- AbbVie ( ABBV ) said Monday that its late-stage study comparing upadacitinib, or Rinvoq, with Humira in certain adult patients with moderate to severe rheumatoid arthritis met its primary and most secondary endpoints at week 12, with no new safety concerns. The drugmaker said that a significantly higher number of patients who had...
Copyright 2023-2026 - www.financetom.com All Rights Reserved